Research by DealForma
Decades of context backed by data from the DealForma database
Run your analyses better, in less time, with the newest database built for biopharma, medtech, and diagnostics.
May 2023 Top Biopharma Deal: Cellular Biomedicine development and commercialization deal with Janssen for C-CAR039 and C-CAR066
Introducing: DealForma plus Tableau
We are excited to introduce DealForma's new...
Venture & IPO – Medtech – Q1 2023
The Medtech sector encompasses medical devices,...
Drug Sales Figures
All of this by stage, disease indication, modality, target…
M&A – Biopharma Therapeutics And Platforms – Q1 2023
Biopharma M&A started to in the first quarter of 2023 after a slow 2022. Major deals included Moderna's acquisition of OriCiro Genomics for $85 million, expanding Moderna's manufacturing capabilities for mRNA vaccines. Pfizer's blockbuster $43 billion acquisition...
R&D Partnerships – Biopharma Therapeutics And Platforms – Q1 2023
First quarter 2023 R&D partnerships for biopharma therapeutics and platforms followed very similar trends from 2022 with continued declines in venture investment and dealmaking. One area that did pick up slightly in the total Q1 2023 numbers was biopharma M&A,...
Biopharma Venture & IPOs – Therapeutics and Platforms: Q1 2023 Review
The slowdown in interest rate hikes may increase small biotech companies' initial public offerings (IPOs) later in 2023. Investors will be more cautious and favor firms with drugs in human trials. The biotech industry experienced a decline in IPOs globally in 2022 due...
Healthcare and Life Sciences Q1 2023 Review: Licensing Partnerships
There has been a significant decrease in R&D licensing and partnership activity from the previous quarter, dropping from $55.9 billion to $35.4 billion in Q1 2023. Q1 2023 R&D Partnerships Set to Drive Growth $35.4 billion in total R&D partnership deal...
Healthcare and Life Sciences Q1 2023 Review: IPOs and SPACs
Biopharma IPOs as Investors Bet On Life-Saving Breakthroughs Only $400 million in 3 newly filed IPOs were raised in Q1 2023 - 1 fewer IPO filing compared to Q4 2022 but with a slightly higher value vs. $300 million raised in Q4 2022. Q2 of 2021 saw the most...
April 2023 Top Biopharma Deal: DualityBio development and commercialization deal with BioNTech for DB-1303 and DB-1311 for cancer
Healthcare and Life Sciences Q1 2023 Review: Venture Capital
Venture capital investment activity in Q1 2023 was down across multiple industries, including biopharma. Biopharma venture fundraising looked much like 2022, which looked much like 2019. As before, biopharma fared slightly better than medtech, diagnostics, tools, and...
Healthcare and Life Sciences Q1 2023 Review: Mergers & Acquisitions
First quarter 2023 deal activity followed very similar trends from 2022 with continued declines in venture investment and dealmaking. One area that did pick up slightly in the total Q1 numbers was biopharma M&A, mainly driven by early January acquisition activity...
R&D Partnerships, M&A, Ventures, and IPOs by TA – Neurology
R&D Partnerships, M&A, Ventures, and IPOs by TA – Neurology The biotech industry is facing a critical moment as it enters 2023. The previous year was challenging for the sector, as initial public offerings decreased, and a biotech stock index declined by...
March 2023 Top Biopharma Deal: OncoC4 – BioNTech for ONC-392 for Solid Tumors and NSCLC
Biopharma Deals and Funding Trends – Review of 2022 and Updates through Q1 2023
Deal Flow in 2022 Returned to pre-2019 Levels Lower Deal Dollars Across All Healthcare and Life Sciences Licensing Terms are Shifting to More in Milestones Large Cap Biopharma In-Licensing and Buying in 2022 Big...
R&D Partnerships, M&A, Ventures, & IPOs in T.A. – Cancer
R&D Partnerships, M&A, Ventures, & IPOs in T.A. – Cancer The pharmaceutical industry continues to place significant emphasis on cancer treatment. A report by the International Agency for Cancer Research suggests that the number of deaths resulting from...
Venture & IPO – Medtech
Venture & IPO - Medtech As the demand for innovative medical technologies continues to grow, many entrepreneurs and investors are exploring ways to finance the development and commercialization of new MedTech products. Two popular options for raising capital in...
M&A – Medtech
M&A – Medtech Medical technology, or MedTech, is a multidisciplinary field that combines technology and medical interventions. It encompasses various technologies, devices, services, products, and solutions that employ medical technology to improve patient care...
R&D Partnerships – Medtech
R&D PARTNERSHIPS – MEDTECH As we enter the first quarter of 2023, there is a persistent rise in R&D spending despite the mounting pressure to cut costs, reduce budgets and enhance profit margins. The life sciences sector anticipated an R&D expenditure of...
Biopharma Reverse Mergers And SPACs– What Happened Since 2020
Biopharma Reverse Mergers And SPACs– What Happened Since 2020 The biopharmaceutical industry has seen a significant uptick in using reverse mergers and Special Purpose Acquisition Companies (SPACs) to go public since 2020. This trend has been partly driven by the...
M&A – Biopharma Therapeutics And Platforms
M&A – Biopharma Therapeutics And Platforms Mergers and Acquisitions are related concepts that refer to consolidating two or more companies into a single entity. In a merger, two or more companies come together to form a new company, while in an acquisition, one...
R&D Partnerships – Biopharma Therapeutics And Platforms
R&D Partnerships - Biopharma Therapeutics And Platforms R&D partnerships are common in the biopharmaceutical industry. Typically, these partnerships involve two or more companies or organizations collaborating to research, develop, and commercialize new drugs...
February 2023 Top Biopharma Deal: Axsome – Pharmanovia for EDS Drug Sunosi
January 2023 Top Biopharma Deal: Hutchmed – Takeda for cancer drug fruquintinib
Biopharma Therapeutics & Platforms Paradigm
Biopharma Therapeutics & Platforms Paradigm Biopharmaceutical companies that develop new therapies and health technologies are essential for advancing drug development in its early stages. That's why US biotech firms are highly sought after by private equity...
2022 Year in Review and Future Insights
The recent decline in U.S. GDP and the risk of recession are significant factors affecting the biopharma sector. The capital markets for biopharma assets are challenging, with difficulties in valuations, accessing the IPO market, and raising new capital. The closing...
December 2022 Top Biopharma Deal: Akeso – Summit for Cancer Drug Ivonescimab
November 2022 Top Biopharma Deal: POINT – Lantheus for cancer drugs PNT2002 and PNT2003
October 2022 Top Biopharma Deal: MacroGenics – Gilead for blood cancer drug MGD024
September 2022 Top Biopharma Deal: SpringWorks – GSK for Nirogacestat in combination with Blenrep
August 2022 Top Biopharma Deal: Sanofi – Innovent for Cancer Drugs SAR408701 and SAR444245
July 2022 Top Biopharma Deal: Orion – MSD for Prostate Cancer Drug ODM-208
June 2022 Top Biopharma Deal: Sanofi – Regeneron Pharmaceuticals for Cancer/Inflammation drug Libtayo
May 2022 Top Biopharma Deal: Dragonfly Therapeutics – Gilead Sciences NK cell engager for cancer/inflammation
April 2022 Top Biopharma Deal: Harbour BioMed – AstraZeneca Bispecific Antibody for Cancer Treatment
March 2022 Top Biopharma Deal: IGM Biosciences – Sanofi IgM Antibody Platform for Cancer and Immunology/Inflammation
February 2022 Top Biopharma Deal: Heidelberg – Huadong ATAC Candidates for Cancer Treatment
January 2022 Top Biopharma Deal: Beam – Pfizer In Vivo Base Editing and Delivery Programs for Rare Diseases
December 2021 Top Biopharma Deal: Foghorn – Loxo using Gene Traffic Control for New Oncology Treatments
November 2021 Top Biopharma Deal: Sanofi – Owkin artificial intelligence and federated learning platform to advance Sanofi’s oncology pipeline
October 2021 Top Biopharma Deal: Xencor – Janssen for Plamotamab and XmAb Bispecific Antibodies
September 2021 Top Biopharma Deal: REGENXBIO – AbbVie for RBX-314 for wet AMD, diabetic retinopathy
August 2021 Top Biopharma Deal: RemeGen – Seagen HER2-targeted ADC, Disitamab Vedotin for Solid Tumors
Top Biopharma Deal July 2021: Arvinas – Pfizer ARV-471 PROTAC Protein Degrader for ER+/HER2- Breast Cancer
Top Biopharma Deal June 2021: iTeos – GSK for EOS-448 anti-TIGIT mAb for Solid Tumors
May 2021 Top Biopharma Deal: Agenus – BMS for AGEN-1777 Bispecific Anti-TIGIT Antibody for Non-Small Cell Lung Cancer
Top Biopharma Deal April 2021: CRISPR – Vertex for CTX001 for Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia
Top Biopharma Deal March 2021: Debiopharm – Merck KGaA for Xevinapant for head and neck cancer
Biotech and Pharma Deals in 2020
Biotech and pharma deals in 2020 soared to an all-time high of 1,154 signed deals with $146.3 billion in total value, defying expectations that the global Covid-19 pandemic would hamper dealmaking. Global healthcare and life sciences R&D partnership activity was...
Biopharma Deal of the Month: Vir – GSK for VIR-2482 and mAbs for Influenza
Biotech and Pharma M&A in 2020
Biotech and pharma M&A total deal values slumped in 2020, despite an active year in life sciences dealmaking, with no big standout biopharma deals until late in the second half of the year. It could also be argued that big M&A deals were put on a backburner as...
Life Sciences M&A Tops $240 Billion in 2019
This article is a sample from the DealForma Annual Deal Trends Report provided to database subscribers. Data for this analysis was compiled using the DealForma biopharma deals database. We applied initial filters for mergers and acquisitions, therapeutic areas, asset...